Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renov ...

Renovaro's merger with BioSymetrics is designed to enhance Renovaro's data repository and biomarker discovery capabilities, ...

NEW YORK, NY / ACCESS Newswire / April 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...

NEW YORK, NY / ACCESS Newswire / April 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...

Supernus Pharmaceuticals got a positive adjustment to its Relative Strength (RS) Rating, from 67 to 81. Please watch the ...

Prudential Financial Inc.’s holdings in Supernus Pharmaceuticals were worth $2,374,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals (NASDAQ:SUPN) develops and markets treatments for central nervous system ...

Collegium Pharmaceutical reported revenues of $181.9 million, up 21.5% year on year. This print exceeded analysts’ ...

Solriamfetol, a new treatment for ADHD, showed a 45% reduction in symptoms in a Phase 3 trial. This treatment targets ...

Supernus has boosted its position in central nervous system therapies with a $400 million deal to acquire Adamas Pharma that will add two approved Parkinson's disease therapies to its stable.